ArticleFrontiers in cellular neuroscience2014
Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.
Article in Frontiers in cellular neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- The Aging Immune System: A Critical Attack on Ischemic Stroke.Molecular neurobiology · 2025Review
- Ischemic Preconditioning Modulates the Peripheral Innate Immune System to Promote Anti-Inflammatory and Protective Responses in Mice Subjected to Focal Cerebral Ischemia.Frontiers in immunology · 2022Article
- Targeting Brain-spleen Crosstalk After Stroke: New Insights Into Stroke Pathology and Treatment.Current neuropharmacology · 2021Review
- IL-2mAb reduces demyelination after focal cerebral ischemia by suppressing CD8CNS neuroscience & therapeutics · 2019Article
- The spleen may be an important target of stem cell therapy for stroke.Journal of neuroinflammation · 2019Review
- Nursing Markedly Protects Postpartum Mice From Stroke: Associated Central and Peripheral Neuroimmune Changes and a Role for Oxytocin.Frontiers in neuroscience · 2019Article
- Uncovering the Rosetta Stone: Report from the First Annual Conference on Key Elements in Translating Stroke Therapeutics from Pre-Clinical to Clinical.Translational stroke research · 2018Article
- Splenectomy protects aged mice from injury after experimental stroke.Neurobiology of aging · 2018Article
- Partial MHC class II constructs as novel immunomodulatory therapy for stroke.Neurochemistry international · 2017Review
- Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.Neurochemistry international · 2017Article
- Sex differences in the immune response to experimental stroke: Implications for translational research.Journal of neuroscience research · 2017Review
- Neuroprotective Properties of a Macrolide Antibiotic in a Mouse Model of Middle Cerebral Artery Occlusion: Characterization of the Immunomodulatory Effects and Validation of the Efficacy of Intravenous Administration.Assay and drug development technologies · 2016Article
- Partial MHC Constructs Treat Thromboembolic Ischemic Stroke Characterized by Early Immune Expansion.Translational stroke research · 2016Article
- Astrocytic response to cerebral ischemia is influenced by sex differences and impaired by aging.Neurobiology of disease · 2016Review
- Editorial: Mechanisms of neuroinflammation and inflammatory neurodegeneration in acute brain injury.Frontiers in cellular neuroscience · 2015Article
- Targeting the peripheral inflammatory response to stroke: role of the spleen.Translational stroke research · 2014Article
- Commentary: Different immunological mechanisms govern protection from experimental stroke in young and older mice with recombinant TCR ligand therapy.Frontiers in cellular neuroscience · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Stroke is a leading cause of death and disability in the United States. The lack of clinical success in stroke therapies can be attributed, in part, to inadequate basic research on aging rodents. The current study demonstrates that recombinant TCR ligand therapy uses different immunological mechanisms to protect young and older mice from experimental stroke. In young mice, RTL1000 therapy inhibited splenocyte efflux while reducing frequency of T cells and macrophages in the spleen. Older mice treated with RTL1000 exhibited a significant reduction in inflammatory cells in the brain and inhibition of splenic atrophy. Our data suggest age specific differences in immune response to stroke that allow unique targeting of stroke immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.